About innoviva inc - INVA
Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
INVA At a Glance
Innoviva, Inc.
1350 Old Bayshore Highway
Burlingame, California 94010
| Phone | 1-650-238-9600 | Revenue | 425.13M | |
| Industry | Pharmaceuticals: Major | Net Income | 271.17M | |
| Sector | Health Technology | 2025 Sales Growth | 14.125% | |
| Fiscal Year-end | 12 / 2026 | Employees | 159 | |
| View SEC Filings |
INVA Valuation
| P/E Current | 7.00 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 6.055 |
| Price to Sales Ratio | 3.986 |
| Price to Book Ratio | 1.272 |
| Price to Cash Flow Ratio | 8.60 |
| Enterprise Value to EBITDA | 6.847 |
| Enterprise Value to Sales | 3.285 |
| Total Debt to Enterprise Value | 0.193 |
INVA Efficiency
| Revenue/Employee | 2,673,761.006 |
| Income Per Employee | 1,705,440.252 |
| Receivables Turnover | 4.556 |
| Total Asset Turnover | 0.286 |
INVA Liquidity
| Current Ratio | 14.639 |
| Quick Ratio | 13.851 |
| Cash Ratio | 11.403 |
INVA Profitability
| Gross Margin | 72.335 |
| Operating Margin | 38.517 |
| Pretax Margin | 76.886 |
| Net Margin | 63.784 |
| Return on Assets | 18.256 |
| Return on Equity | 29.095 |
| Return on Total Capital | 18.807 |
| Return on Invested Capital | 22.691 |
INVA Capital Structure
| Total Debt to Total Equity | 22.937 |
| Total Debt to Total Capital | 18.658 |
| Total Debt to Total Assets | 16.452 |
| Long-Term Debt to Equity | 22.902 |
| Long-Term Debt to Total Capital | 18.629 |